Overview
- Final-day bids showed a sharp split, with Corona Remedies subscribed about 120.58 times versus roughly 2.12 times for Wakefit Innovations.
- Grey market quotes pointed to roughly 25–31% potential listing gains for Corona, while Wakefit signaled flat to negligible upside.
- Corona’s Rs 655.37 crore issue was a fully offer-for-sale priced at Rs 1,008–1,062 with a 14-share lot, whereas Wakefit’s Rs 1,288.89 crore offer combined a Rs 377.18 crore fresh issue with a large OFS at Rs 185–195 and a 76-share lot.
- Brokerages largely advised subscribing to Corona on growth and margins, but many flagged Wakefit’s losses, thin margins and valuation as reasons to be cautious or avoid.
- Allotments are expected on December 11 and both stocks are slated to list on the BSE and NSE on December 15.